XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenon Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$35.08+1.59 (+4.75%)
Close on Oct 19, 2026
- Market cap
- $3.49B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
101M of 97M shares
Institutional holders
315
50 new, 22 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 26 sales
Net sold $21.97M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 9,959,795 | 10.30% | 13G (passive) amendment | Jul 31, 2026 |
| Behzad Aghazadeh | 5,777,777 | 6.26% | 13G (passive) amendment | Mar 31, 2026 |
| Wellington Management Company LLP | 4,764,779 | 6.00% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 4,757,709 | 6.20% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XENE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,647,998 | 9.96% | $582.35M | −1,170,493 | 0.03% |
| BlackRock, Inc. | 7,522,482 | 7.77% | $454.06M | +1,882,364 | 0.01% |
| Avoro Capital Advisors LLC | 5,777,777 | 5.97% | $348.75M | – | 3.13% |
| Polar Capital Holdings Plc | 4,570,556 | 4.72% | $275.88M | +165,244 | 0.65% |
| Driehaus Capital Management LLC | 4,418,557 | 4.56% | $266.70M | −73,096 | 1.55% |
| Jupiter Topco LLC | 4,186,519 | 4.32% | $252.67M | New | 0.10% |
| Price T Rowe Associates Inc /Md/ | 3,248,219 | 3.35% | $196.06K | +1,918,628 | 0.02% |
| JPMorgan Chase & Co | 2,617,360 | 2.70% | $157.38M | +693,750 | 0.01% |
| Capital International Investors | 2,361,639 | 2.44% | $142.55M | −313,088 | 0.03% |
| T. Rowe Price Investment Management, Inc. | 2,168,581 | 2.24% | $130.90K | +1,216,626 | 0.09% |
| State Street Corp | 1,969,629 | 2.03% | $118.89M | +249,096 | 0.00% |
| Two Sigma Investments, LP | 1,642,848 | 1.70% | $99.16M | +1,036,763 | 0.07% |
| Deerfield Management Company, L.P. (Series C) | 1,615,696 | 1.67% | $97.52M | – | 1.02% |
| Affinity Asset Advisors, LLC | 1,595,000 | 1.65% | $96.27M | −80,000 | 4.35% |
| Alliancebernstein L.P. | 1,562,276 | 1.61% | $90.85M | +158,979 | 0.03% |
| Westfield Capital Management Co LP | 1,507,294 | 1.56% | $90.98M | +105,811 | 0.30% |
| Franklin Resources Inc | 1,437,712 | 1.48% | $86.78M | +157,135 | 0.02% |
| Wellington Management Group Llp | 1,425,492 | 1.47% | $86.04M | −3,404,149 | 0.01% |
| Citadel Advisors LLC | 1,401,242 | 1.45% | $84.58M | −1,251,748 | 0.01% |
| Geode Capital Management, LLC | 1,370,114 | 1.41% | $82.69M | +277,182 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 315 | 101M | 100.0% | 50 / 125 | 87 / 22 | 20M | 15M |
| Q1 2026 | 290 | 100M | 100.0% | 81 / 124 | 60 / 33 | 24M | 7M |
| Q4 2025 | 246 | 85M | 87.3% | 51 / 82 | 74 / 22 | 10M | 11M |
| Q3 2025 | 219 | 86M | 88.5% | 35 / 68 | 71 / 20 | 10M | 7M |
| Q2 2025 | 206 | 83M | 86.0% | 42 / 76 | 56 / 40 | 19M | 13M |
| Q1 2025 | 206 | 77M | 79.3% | 20 / 70 | 72 / 23 | 7M | 6M |
| Q4 2024 | 209 | 76M | 78.8% | 29 / 65 | 70 / 21 | 6M | 5M |
| Q3 2024 | 203 | 76M | 78.4% | 15 / 74 | 63 / 24 | 10M | 7M |
| Q2 2024 | 213 | 75M | 77.5% | 21 / 78 | 71 / 27 | 6M | 6M |
| Q1 2024 | 220 | 75M | 77.7% | 36 / 79 | 67 / 19 | 8M | 6M |
| Q4 2023 | 204 | 73M | 75.6% | 46 / 87 | 50 / 19 | 18M | 8M |
| Q3 2023 | 180 | 63M | 64.5% | 22 / 72 | 51 / 15 | 8M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of XENE | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 3,124,659 | 3.23% | $188.60M | 0.20% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,519,578 | 2.60% | $152.08M | 0.18% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,937,648 | 2.00% | $106.05M | 0.04% | May 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 1,274,673 | 1.32% | $76.94M | 0.11% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,150,000 | 1.19% | $62.94M | 1.09% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,072,877 | 1.11% | $67.24M | 0.20% | Jul 31, 2026 |
| JPMorgan Mid Cap Growth Fund | 962,101 | 0.99% | $58.07M | 0.44% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 906,147 | 0.94% | $54.70M | 0.35% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 902,587 | 0.93% | $54.48M | 0.37% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 853,241 | 0.88% | $51.50M | 0.52% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 780,761 | 0.81% | $48.93M | 0.56% | Jul 31, 2026 |
| Small Cap Growth Fund | 668,917 | 0.69% | $41.92M | 0.75% | Jul 31, 2026 |
| iShares Biotechnology ETF | 642,923 | 0.66% | $38.81M | 0.43% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 591,185 | 0.61% | $37.05M | 0.50% | Jul 31, 2026 |
| Federated Hermes Kaufmann Fund | 522,500 | 0.54% | $32.75M | 0.66% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO, Director | 34,223 | 0.04% | Mar 13, 2026 |
| Christopher John Kenney | Chief Medical Officer | 2 | 0.00% | Aug 31, 2026 |
| Andrea DiFabio | Chief Legal Officer | 7,301 | 0.01% | Mar 13, 2026 |
| Darren S. Cline | Chief Commercial Officer | 0 | – | Jan 9, 2026 |
| Thomas Patrick Kelly | Chief Financial Officer | 0 | – | Oct 17, 2025 |
| Sherry Aulin | Chief Financial Officer | 0 | – | Dec 19, 2024 |
| Dawn Svoronos | Director | 31,373 | 0.03% | Sep 3, 2026 |
| Steven Gannon | Director | 1,870 | 0.00% | Aug 13, 2026 |
| Gary Patou | Director | 29,798 | 0.03% | Jun 8, 2026 |
| Gillian Cannon | Director | 1,455 | 0.00% | Jun 8, 2026 |
| Patrick Machado | Director | 2,645 | 0.00% | Jun 3, 2026 |
| Justin D. Gover | Director | 2,645 | 0.00% | Jun 3, 2026 |
| Elizabeth A. Garofalo | Director | 2,645 | 0.00% | Jun 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dawn Svoronos Director | Sep 1, 2026 | Option exercise | +5,144 | $8.15 | $41.92K | 31,373 |
| Christopher John Kenney Chief Medical Officer | Aug 28, 2026 | Sale(10b5-1 plan) | −700 | $60.98 | $42.69K | 2 |
| Christopher John Kenney Chief Medical Officer | Aug 28, 2026 | Sale(10b5-1 plan) | −6,368 | $60.17 | $383.16K | 702 |
| Steven Gannon Director | Aug 11, 2026 | Sale | −10,000 | $64.06 | $640.60K | 1,870 |
| Gary Patou Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,322 | $53.14 | $70.25K | 24,896 |
| Gillian Cannon Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,190 | $53.14 | $63.24K | 1,455 |
| Dawn Svoronos Director | Jun 1, 2026 | Tax withholding | −1,416 | $53.41 | $75.63K | 26,229 |
| Dawn Svoronos Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 27,645 |
| Justin D. Gover Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Patrick Machado Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Steven Gannon Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 13,286 |
| Steven Gannon Director | Jun 1, 2026 | Tax withholding | −1,416 | $53.41 | $75.63K | 11,870 |
| Gary Patou Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 26,218 |
| Gillian Cannon Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Elizabeth A. Garofalo Director | Jun 1, 2026 | Option exercise | +2,645 | – | – | 2,645 |
| Steven Gannon Director | May 12, 2026 | Option exercise | +3,500 | $7.38 | $25.83K | 10,641 |
| Christopher John Kenney Chief Medical Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −1,410 | $55.23 | $77.87K | 7,069 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 13, 2026 | Sale(10b5-1 plan) | −7,308 | $55.23 | $403.62K | 19,923 |
| Andrea DiFabio Chief Legal Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −1,342 | $55.23 | $74.12K | 7,301 |
| Christopher John Kenney Chief Medical Officer | Mar 12, 2026 | Option exercise | +3,750 | – | – | 8,479 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 12, 2026 | Option exercise | +12,500 | – | – | 27,231 |
| Andrea DiFabio Chief Legal Officer | Mar 12, 2026 | Option exercise | +3,750 | – | – | 8,643 |
| Christopher John Kenney Chief Medical Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −2,771 | $60.11 | $166.56K | 4,729 |
| Andrea DiFabio Chief Legal Officer | Mar 10, 2026 | Sale(10b5-1 plan) | −2,607 | $60.11 | $156.71K | 4,893 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 10, 2026 | Sale(10b5-1 plan) | −11,269 | $60.11 | $677.38K | 14,731 |
| Christopher John Kenney Chief Medical Officer | Mar 9, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Andrea DiFabio Chief Legal Officer | Mar 9, 2026 | Option exercise | +7,500 | – | – | 7,500 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +20,000 | – | – | 26,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −65,000 | $62.06 | $4.03M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +65,000 | $9.44 | $613.60K | 71,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −61,652 | $60.08 | $3.70M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −43,348 | $59.26 | $2.57M | 72,652 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +105,000 | $4.75 | $498.75K | 111,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −2,449 | $61.26 | $150.03K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −10,072 | $60.47 | $609.05K | 8,449 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −12,479 | $59.50 | $742.50K | 18,521 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +25,000 | $3.10 | $77.50K | 31,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −21,515 | $60.49 | $1.30M | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −31,694 | $59.88 | $1.90M | 27,515 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −21,791 | $58.81 | $1.28M | 59,209 |
| Ian Mortimer PRESIDENT & CEO, Director | Mar 9, 2026 | Option exercise | +75,000 | $8.40 | $630.00K | 81,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −2,062 | $44.93 | $92.65K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Option exercise | +40,000 | $7.49 | $299.60K | 46,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −37,938 | $44.40 | $1.68M | 8,062 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −8,820 | $45.59 | $402.10K | 8,010 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −2,010 | $46.32 | $93.10K | 6,000 |
| Ian Mortimer PRESIDENT & CEO, Director | Dec 5, 2025 | Sale(10b5-1 plan) | −14,375 | $45.03 | $647.31K | 16,830 |
| Ian Mortimer PRESIDENT & CEO, Director | Nov 28, 2025 | Sale(10b5-1 plan) | −97 | $45.01 | $4.37K | 31,205 |
| Ian Mortimer PRESIDENT, CEO & INTERIM CFO, Director | Oct 1, 2025 | Option exercise | +25,000 | $7.69 | $192.25K | 56,302 |
| Ian Mortimer PRESIDENT, CEO & INTERIM CFO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −25,000 | $40.16 | $1.00M | 31,302 |
| Steven Gannon Director | Jun 5, 2025 | Sale | −3 | $30.48 | $91 | 7,141 |
| Steven Gannon Director | May 14, 2025 | Option exercise | +5,144 | $12.57 | $64.66K | 7,144 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Option exercise | +15,166 | $17.76 | $269.35K | 46,468 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Sale(10b5-1 plan) | −1,149 | $41.07 | $47.19K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Sale(10b5-1 plan) | −15,166 | $40.46 | $613.62K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 27, 2025 | Option exercise | +1,149 | $17.76 | $20.41K | 32,451 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 24, 2025 | Sale(10b5-1 plan) | −22,468 | $40.20 | $903.21K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 24, 2025 | Option exercise | +22,468 | $17.76 | $399.03K | 53,770 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 23, 2025 | Sale(10b5-1 plan) | −16,217 | $40.08 | $649.98K | 31,302 |
| Ian Mortimer PRESIDENT & CEO, Director | Jan 23, 2025 | Option exercise | +16,217 | $17.76 | $288.01K | 47,519 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kenney Christopher Officer | Aug 28, 2026 | 7,068 | $437.72K | Aug 28, 2026 | Restricted and Performance Stock Units |
| Gannon Steven Director | Aug 13, 2026 | 10,000 | $640.55K | Aug 11, 2026 | Open Market Purchase |
| Patou Gary Director | Jun 5, 2026 | 1,322 | $70.05K | Jun 5, 2026 | Restricted Stock Units |
| Cannon Gillian Director | Jun 5, 2026 | 1,190 | $63.06K | Jun 5, 2026 | Restricted Stock Units |
| Mortimer Ian Officer, Director | Mar 13, 2026 | 7,308 | $403.58K | Mar 13, 2026 | Restricted share unit award vesting |
| Difabio Andrea Officer | Mar 13, 2026 | 1,342 | $74.11K | Mar 13, 2026 | Restricted share unit award vesting |
| John Kenney Christopher Officer | Mar 13, 2026 | 1,410 | $77.87K | Mar 13, 2026 | Restricted share unit award vesting |
| Mortimer Ian Officer, Director | Mar 10, 2026 | 11,269 | $677.36K | Mar 10, 2026 | Performance share unit award vesting |
| John Kenney Christopher Officer | Mar 10, 2026 | 2,771 | $166.56K | Mar 10, 2026 | Performance share unit award vesting |
| Difabio Andrea Officer | Mar 10, 2026 | 2,607 | $156.70K | Mar 10, 2026 | Performance share unit award vesting |
| Mortimer Ian Officer, Director | Mar 9, 2026 | 270,000 | $16.29M | Mar 9, 2026 | Exercise of Options |
| Mortimer Ian Officer, Director | Jan 2, 2026 | 40,000 | $1.78M | Jan 2, 2026 | Exercise of Options |
| Mortimer Ian Officer, Director | Dec 8, 2025 | 10,830 | $495.25K | Dec 8, 2025 | Exercise of Options |
| Mortimer Ian Officer, Director | Dec 5, 2025 | 14,375 | $647.36K | Dec 5, 2025 | Exercise of Options |
| Mortimer Ian Officer, Director | Dec 1, 2025 | 97 | $4.37K | Nov 28, 2025 | Exercise of Options |